
Suzette Delaloge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8189667/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 2007, 13, 1050-1059.	30.7	2,657
2	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. New England Journal of Medicine, 2017, 377, 523-533.	27.0	2,256
3	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. New England Journal of Medicine, 2016, 375, 717-729.	27.0	1,427
4	Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	30.7	823
5	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunological Reviews, 2007, 220, 47-59.	6.0	491
6	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	10.7	451
7	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 367-377.	10.7	444
8	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. Journal of Clinical Oncology, 2004, 22, 3302-3308.	1.6	389
9	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	12.6	367
10	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	27.0	363
11	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	1.2	354
12	Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial. Clinical Cancer Research, 2008, 14, 7004-7010.	7.0	350
13	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. Clinical Cancer Research, 2009, 15, 441-451.	7.0	300
14	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 8331-8339.	1.6	266
15	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	1.6	244
16	Dual-energy contrast-enhanced digital mammography: initial clinical results. European Radiology, 2011, 21, 565-574.	4.5	233
17	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer, 2018, 96, 17-24.	2.8	211
18	Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer. Journal of the American College of Cardiology, 2011, 57, 445-452.	2.8	191

#	Article	IF	CITATIONS
19	Laser thermal therapy: Realâ€ŧime MRIâ€guided and computerâ€controlled procedures for metastatic brain tumors. Lasers in Surgery and Medicine, 2011, 43, 943-950.	2.1	184
20	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncology, The, 2021, 22, 476-488.	10.7	179
21	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	27.6	178
22	An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. American Journal of Surgery, 2003, 185, 158-164.	1.8	175
23	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	10.7	161
24	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€^864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	10.7	147
25	Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer. Journal of Clinical Oncology, 2007, 25, 292-300.	1.6	140
26	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	2.2	135
27	<i>CDH1</i> germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. Journal of Medical Genetics, 2013, 50, 486-489.	3.2	131
28	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. British Journal of Cancer, 2019, 121, 991-1000.	6.4	113
29	Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions. European Journal of Radiology, 2014, 83, 773-777.	2.6	103
30	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. European Journal of Cancer, 2020, 129, 60-70.	2.8	103
31	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Research and Treatment, 2010, 122, 429-437.	2.5	99
32	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy, 2015, 11, 1878-1890.	9.1	91
33	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy, 2016, 12, 864-875.	9.1	90
34	Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. Cancer Research, 2013, 73, 2247-2258.	0.9	86
35	New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. European Journal of Radiology, 2009, 69, 14-23.	2.6	82
36	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	1.6	80

#	Article	IF	CITATIONS
37	Triple-negative breast cancer: are we making headway at least?. Therapeutic Advances in Medical Oncology, 2012, 4, 195-210.	3.2	75
38	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer, 2019, 120, 20-30.	2.8	75
39	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	11.2	72
40	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Investigational New Drugs, 2012, 30, 1193-1202.	2.6	71
41	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
42	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). Journal of Clinical Oncology, 2020, 38, 734-743.	1.6	69
43	Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. Journal of Clinical Oncology, 2011, 29, 1236-1238.	1.6	65
44	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer, 2004, 101, 918-925.	4.1	62
45	The role of Oncoplastic Breast Surgery in the management of breast cancer treated with primary chemotherapy. Breast, 2013, 22, 1189-1193.	2.2	60
46	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. Oncologist, 2009, 14, 1182-1188.	3.7	59
47	Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiotherapy and Oncology, 2010, 96, 199-203.	0.6	59
48	Exploring frontiers: Use of complementary and alternative medicine among patients with early-stage breast cancer. Breast, 2014, 23, 279-285.	2.2	59
49	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncology, The, 2019, 20, 361-370.	10.7	59
50	Ki67—no evidence for its use in node-positive breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 296-301.	27.6	58
51	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer, 2006, 107, 1459-1466.	4.1	55
52	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncology, The, 2009, 10, 381-390.	10.7	55
53	SARS-CoV-2 vaccines for cancer patients: a call to action. European Journal of Cancer, 2021, 148, 316-327.	2.8	55
54	Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Research, 2007, 27, 547-55.	1.1	51

#	Article	IF	CITATIONS
55	Chk1 as a new therapeutic target in triple-negative breast cancer. Breast, 2014, 23, 250-258.	2.2	50
56	Therapeutic vaccines for breast cancer: Has the time finally come?. European Journal of Cancer, 2022, 160, 150-174.	2.8	49
57	MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients Journal of Clinical Oncology, 2020, 38, 506-506.	1.6	44
58	Outcome in breast molecular subtypes according to nodal status and surgical procedures. American Journal of Surgery, 2013, 205, 662-667.	1.8	43
59	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 341-345.	1.3	39
60	Targeting PI3K/AKT pathway in triple-negative breast cancer. Lancet Oncology, The, 2017, 18, 1293-1294.	10.7	39
61	Added Value of Contrast-Enhanced Spectral Mammography in Postscreening Assessment. Breast Journal, 2016, 22, 520-528.	1.0	38
62	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nature Medicine, 2022, 28, 1224-1231.	30.7	38
63	Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the <scp>E3Nâ€EPIC</scp> cohort. International Journal of Cancer, 2016, 138, 2415-2427.	5.1	37
64	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. British Journal of Cancer, 2021, 125, 1486-1493.	6.4	37
65	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. European Journal of Cancer, 2016, 66, 131-137.	2.8	33
66	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. Npj Breast Cancer, 2021, 7, 41.	5.2	33
67	Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening―(MyPeBS) randomised clinical trial. BMC Cancer, 2022, 22, 507.	2.6	32
68	The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 703-716.	4.2	28
69	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 2021, 11, 408-423.	9.4	28
70	Value of whole breast magnetic resonance elastography added to MRI for lesion characterization. NMR in Biomedicine, 2018, 31, e3795.	2.8	25
71	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	2.8	25
72	Impact of COVID-19 on healthcare organisation and cancer outcomes. European Journal of Cancer, 2021, 153, 123-132.	2.8	25

#	Article	IF	CITATIONS
73	Gemcitabine in Patients With Solid Tumors and Renal Impairment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 289-293.	1.3	23
74	Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience. Breast Journal, 2016, 22, 83-89.	1.0	23
75	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40, 1111-1123.	1.6	23
76	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open, 2022, 12, e055821.	1.9	23
77	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40, 3190-3204.	1.6	23
78	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancerÂpatients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. European Journal of Cancer, 2017, 75, 323-332.	2.8	22
79	Patient-assisted compression helps for image quality reduction dose and improves patient experience in mammography. European Journal of Cancer, 2018, 103, 137-142.	2.8	21
80	Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. Breast Cancer Research and Treatment, 2021, 188, 501-509.	2.5	18
81	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European Journal of Cancer, 2021, 152, 68-77.	2.8	18
82	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. Journal of Clinical Oncology, 2022, 40, 2148-2162.	1.6	18
83	Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety. Breast Journal, 2018, 24, 154-160.	1.0	17
84	Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG) Tj ETQq0	0 @. ஜBT /	Oværlock 10
85	Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast, 2021, 55, 16-24.	2.2	17
86	Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial Journal of Clinical Oncology, 2020, 38, 2000-2000.	1.6	17
87	Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. Analytical Chemistry, 2022, 94, 6297-6303.	6.5	13
88	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. European Journal of Cancer, 2022, 166, 300-308.	2.8	11
89	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3699-3708.	1.6	11
90	UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup. European Journal of Cancer, 2019, 122, 91-100.	2.8	8

#	Article	IF	CITATIONS
91	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncolmmunology, 2021, 10, 1859064.	4.6	6
92	Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. Breast, 2021, 60, 138-146.	2.2	5
93	A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016― European Journal of Cancer, 2020, 140, 165-166.	2.8	4
94	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. Cancer Research, 2020, 80, 2190-2203.	0.9	4
95	Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. Breast Cancer Research, 2021, 23, 9.	5.0	4
96	MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40–70: Focus on recruitment strategy in France. La Presse Médicale Open, 2022, 3, 100022.	0.4	4
97	Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?. European Journal of Cancer, 2017, 85, 23-30.	2.8	3
98	Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual & volumetric analysis. British Journal of Radiology, 2018, 91, 20170163.	2.2	3
99	Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality. BMJ, The, 2016, 355, i6745.	6.0	2
100	Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008–2016. European Journal of Cancer, 2020, 137, 240-249.	2.8	2
101	BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial. Quality of Life Research, 2021, , 1.	3.1	2
102	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis Journal of Clinical Oncology, 2020, 38, 1087-1087.	1.6	2
103	Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project. PLoS ONE, 2021, 16, e0255017.	2.5	1
104	Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials Journal of Clinical Oncology, 2014, 32, 11087-11087.	1.6	1
105	Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. Breast Journal, 2016, 22, 96-100.	1.0	0
106	Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?. European Journal of Cancer, 2017, 77, 153-154.	2.8	0
107	All simulation models of breast cancer are wrong but some are useful. The Lancet Global Health, 2018, 6, e818-e819.	6.3	0
108	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period Journal of Clinical Oncology, 2014, 32, 1082-1082.	1.6	0

#	Article	IF	CITATIONS
109	Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial Journal of Clinical Oncology, 2014, 32, e11528-e11528.	1.6	0
110	Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies Journal of Clinical Oncology, 2020, 38, TPS1107-TPS1107.	1.6	0